טוען...
Pretransplant 4β‐hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation
AIMS: The CYP3A metric 4β‐hydroxycholesterol (4βOHC) has been shown to correlate with tacrolimus steady‐state apparent oral clearance (CL/F). Recently, pretransplant 4βOHC was shown not to predict tacrolimus CL/F after transplantation in a cohort of renal recipients (n = 79). The goal of the current...
שמור ב:
| הוצא לאור ב: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5651327/ https://ncbi.nlm.nih.gov/pubmed/28603840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13343 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|